Drug targeting clear cell renal cell carcinoma shows promising approach
In a groundbreaking phase one clinical trial led by UT Southwestern Medical Center, a short interfering RNA (siRNA) drug directed to tumor cells effectively disrupted HIF2α, a key driver of clear cell renal cell carcinoma (ccRCC). Published in...
23-Apr-2024 11:05 AM EDT
Add to Favorites